Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Article* "Development of the European Network in Orphan Cardiovascular Diseases" „Rozszerzenie Europejskiej Sieci Współpracy ds Sierocych Chorób Kardiologicznych” Title: Supportive therapy in pulmonary hypertension associated with congenital heart disease. RCD code: II.1.A.4.d Author: Grzegorz Kopeć Affiliation: Department of Cardiac and Vascular Diseases, Centre for Rare Cardiovascular Diseases, John Paul II Hospital, Krakow, Poland Date:2014.06.09 John Paul II Hospital in Kraków Jagiellonian University, Institute of Cardiology 80 Prądnicka Str., 31-202 Kraków; tel. +48 (12) 614 33 99; 614 34 88; fax. +48 (12) 614 34 88 e-mail: [email protected] www.crcd.eu Supportive therapy is an important part of care of patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD). It is important that each patient is evaluated regularly by a physician experienced in PAH-CHD. Patients should be advised prophylaxis of infective endocarditis, regular vaccinations against influenza and pneumococcal infections. Women with PAH-CHD should avoid pregnancy and use effective contraception. Infective endocarditis prophylaxis comprises administration of 30-60 min prior to intervention amoxicillin or ampicillin in the dose of 2 g p.o. or i.v. or 50 mg / kg p.o. or i.v. In case of allergy to penicillin, clindamycin 600 mg p.o. or i.v. or 20 mg / kg p.o. or i.v is recommended. This recommendation is for cyanotic patients undergoing dental procedures involving manipulations of the gums and periapical regions of the teeth or perforation of the oral mucosa. It was found that the risk of death of pregnant women with CHD-PAH reaches 28%, which is significantly multiplied when using general anesthesia. Unfortunately, the termination of pregnancy is also a risk. Patients using endothelin receptor antagonists should use double contraception. This is especially true of patients treated with bosentan, which interacts with progesterone pills. In view of the risk of thrombogenicity estrogen preparations should be avoided. Intrauterine devices while effective carry the risk of infective endocarditis. It is necessary to screen for iron deficiency especially in patients with cyanosis. In patients with heart failure signs and symptoms diuretics are recommended. In patients with Eisenmenger's syndrome it is important to avoid excessive dehydration. Patients should avoid heavy physical exertion especially with static load, although regular physical activity limited by symptoms is recommended, and some data suggest the beneficial effects of supervised exercise and rehabilitation. Anticoagulation is recommended only in patients with additional indications for their use, such as atrial fibrillation or the presence of thrombi in the pulmonary arteries. The use of home oxygen therapy is not justified because it does not improve the blood count, exercise capacity or quality of life. Patients with PAH-CHD have often very poor response to cardiac arrhythmias, and therefore they should be treated according to general recommendations. John Paul II Hospital in Kraków Jagiellonian University, Institute of Cardiology 80 Prądnicka Str., 31-202 Kraków; tel. +48 (12) 614 33 99; 614 34 88; fax. +48 (12) 614 34 88 e-mail: [email protected] www.crcd.eu References: 1. D'Alto M, Diller GP. Pulmonary hypertension in adults with congenital heart disease and Eisenmenger syndrome: current advanced management strategies. Heart. 2014 May 14. pii: heartjnl-2014-305574. doi: 10.1136/heartjnl-2014-305574. [Epub ahead of print] 2. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, Moreillon P, de Jesus Antunes M, Thilen U, Lekakis J, Lengyel M, Müller L, Naber CK, Nihoyannopoulos P, Moritz A, Zamorano JL; ESC Committee for Practice Guidelines. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009 Oct;30(19):2369-413. 3. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E; Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC); Association for European Paediatric Cardiology (AEPC); ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010 Dec;31(23):2915-57. 4. Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009 Dec;34(6):1219-63 ……………………………………….. Author’s signature** John Paul II Hospital in Kraków Jagiellonian University, Institute of Cardiology 80 Prądnicka Str., 31-202 Kraków; tel. +48 (12) 614 33 99; 614 34 88; fax. +48 (12) 614 34 88 e-mail: [email protected] www.crcd.eu [** Signing the article will mean an agreement for its publication] John Paul II Hospital in Kraków Jagiellonian University, Institute of Cardiology 80 Prądnicka Str., 31-202 Kraków; tel. +48 (12) 614 33 99; 614 34 88; fax. +48 (12) 614 34 88 e-mail: [email protected] www.crcd.eu